HIF-1α, the principal regulator of hypoxia, is capable of modifying 1–2% of the genome [40] to adapt to a decrease in partial pressure of oxygen and nutrient availability, and HIF-1α-induced genes are those mediated a large number of effects including increased glycolysis, angiogenesis, EMT, and resistance to the tumor chemotherapy [41]. This evidence concerns the gene HIF1A and neoplasm.